BioSim™ anti-Canakinumab (Human) ELISA Kit

(No reviews yet) Write a Review
SKU:
26-E4868
Availability:
Usually Shipped in 5 Working Days
Size:
96 Assays
Storage Conditions:
4ºC
Shipping Conditions:
Gel Pack
Shelf life:
12 months
£1,329.56
Frequently bought together:

Description

Canakinumab is a recombinant human IgG1 kappa monoclonal antibody that binds to and inhibits human IL-1β by preventing the interaction with its receptor and subsequent inflammatory activity. The antibody neither has cross-reactivity with IL-1α nor with the Interleukin 1 receptor, type I (IL1R1). The antibody has been approved to treat cryopyrin-associated periodic syndromes (CAPS). BioSim™ anti-Canakinumab ELISA kit has been developed to detect antibodies to Canakinumab in human serum or plasma. The kit is based on the sandwich ELISA principle wherein controls and samples (serum or plasma) are added in the microtiter plate coated with Canakinumab. After incubation, the wells are washed and the enzymatic activity is detected by the addition of chromogen-substrate. The enzyme-substrate reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies specific for Canakinumab present in the samples and controls. The qualitative test results can be evaluated using cut-off value.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the qualitative measurement of antibodies to Canakinumab in human serum or plasma samples

Summary: N/A

Detection Method: Absorbance (450 nm)

Sample Type: Plasma,Serum

Species Reactivity: Human

Applications: This Sandwich ELISA kit is used for in vitro qualitative determination of antibodies to Canakinumab in human serum and plasma samples

Features & Benefits: Assay Precision: Intra-Assay and Inter-Assay CV < 30%,For in vitro qualitative determination of antibodies to Canakinumab in human serum and plasma samples,Cross Reactivity: Except for Canakinumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins

View AllClose